Novartis Ag (NVS) Change in Taxes (2020 - 2026)
Novartis Ag recorded quarterly Change in Taxes of -$683.0 million in Q1 2026, up 16.09% quarter-over-quarter from -$814.0 million in Q4 2025, and up 14.41% year-over-year from -$597.0 million in Q1 2025.
Novartis Ag's Change in Taxes history runs 7 years deep, the most recent figure standing at -$683.0 million for Q1 2026.
- In Q1 2026, Change in Taxes rose 14.41% year-over-year to -$683.0 million; the TTM figure through Mar 2026 stood at -$2.3 billion (down 10.3% YoY), while the FY2025 annual figure was -$814.0 million, changed N/A from the prior year.
- Change in Taxes came in at -$683.0 million for Q1 2026 at Novartis Ag, up from -$814.0 million in the prior quarter.
- In the past five years, Change in Taxes ranged from a high of $370.0 million in Q1 2023 to a low of -$814.0 million in Q4 2025.
- A 5-year average of -$372.8 million and a median of -$441.0 million in 2024 frame the typical range for Change in Taxes.
- Across the five-year window, Change in Taxes surged 202.76% in 2023 and slumped 412.82% in 2024, its largest moves.
- Novartis Ag's Change in Taxes stood at -$254.0 million in 2022, then soared by 202.76% to $261.0 million in 2023, then sank by 278.16% to -$465.0 million in 2024, then tumbled by 75.05% to -$814.0 million in 2025, then rose by 16.09% to -$683.0 million in 2026.
- According to Business Quant data, Change in Taxes over the past three periods registered -$683.0 million, -$814.0 million, and -$266.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | -683.00 Mn |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | - |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | -81.00 Mn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | - |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 71.00 Mn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | -29.00 Mn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 187.00 Mn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -683.00 Mn |
| Mar 31, 2026 | -683.00 Mn |
| Dec 31, 2025 | -814.00 Mn |
| Dec 31, 2025 | -814.00 Mn |
| Sep 30, 2025 | -266.00 Mn |
| Sep 30, 2025 | -266.00 Mn |
| Jun 30, 2025 | -507.00 Mn |
| Jun 30, 2025 | -507.00 Mn |
| Mar 31, 2025 | -798.00 Mn |
| Mar 31, 2025 | -798.00 Mn |
| Dec 31, 2024 | -465.00 Mn |
| Dec 31, 2024 | -465.00 Mn |
| Sep 30, 2024 | -200.00 Mn |
| Sep 30, 2024 | -200.00 Mn |
| Jun 30, 2024 | -595.00 Mn |
| Jun 30, 2024 | -595.00 Mn |
| Mar 31, 2024 | -441.00 Mn |
| Mar 31, 2024 | -441.00 Mn |
| Dec 31, 2023 | 261.00 Mn |
| Dec 31, 2023 | 261.00 Mn |
| Sep 30, 2023 | -39.00 Mn |
| Sep 30, 2023 | -39.00 Mn |
| Jun 30, 2023 | -403.00 Mn |
| Jun 30, 2023 | -403.00 Mn |
| Mar 31, 2023 | 370.00 Mn |
| Mar 31, 2023 | 370.00 Mn |
| Dec 31, 2022 | -254.00 Mn |
| Dec 31, 2022 | -254.00 Mn |
| Sep 30, 2022 | -257.00 Mn |
| Sep 30, 2022 | -257.00 Mn |
| Jun 30, 2022 | -797.00 Mn |
| Jun 30, 2022 | -797.00 Mn |
| Mar 31, 2022 | -450.00 Mn |
| Mar 31, 2022 | -450.00 Mn |
| Dec 31, 2021 | -645.00 Mn |
| Dec 31, 2021 | -645.00 Mn |
| Sep 30, 2021 | -472.00 Mn |
| Sep 30, 2021 | -472.00 Mn |
| Jun 30, 2021 | -611.00 Mn |
| Jun 30, 2021 | -611.00 Mn |
| Mar 31, 2021 | -391.00 Mn |
| Mar 31, 2021 | -391.00 Mn |
| Dec 31, 2020 | -460.00 Mn |
| Dec 31, 2020 | -460.00 Mn |
| Sep 30, 2020 | -478.00 Mn |
| Sep 30, 2020 | -478.00 Mn |